Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.65 |
| ▸ | TDO2 | P48775 | 8/20 | 0.65 |
| ▸ | EIF4A3 | P38919 | 3/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 3/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24113200 | 0.88 | IDO1 (0.58) | IDO1TDO2EIF4A3HRH4HPGD | |
| SCHEMBL30310603 | 0.88 | IDO1 (0.58) | IDO1TDO2EIF4A3HRH4HPGD | |
| SCHEMBL22747188 | 0.88 | IDO1 (0.75) | IDO1TDO2EIF4A3HRH4HPGD | |
| SCHEMBL29974758 | 0.88 | IDO1 (0.75) | IDO1TDO2EIF4A3HRH4HPGD | |
| SCHEMBL28455734 | 0.86 | KDM4E (0.49) | IDO1TDO2EIF4A3HPGDKDM4E | |
| SCHEMBL28844643 | 0.85 | IDO1 (0.48) | IDO1TDO2EIF4A3HRH4RHEB | |
| SCHEMBL22620603 | 0.81 | XDH (0.50) | IDO1TDO2HRH4HPGDKDM4E | |
| SCHEMBL22394891 | 0.80 | IDO1 (0.65) | IDO1TDO2EIF4A3HRH4RHEB | |
| SCHEMBL20505032 | 0.80 | IDO1 (0.65) | IDO1TDO2EIF4A3HRH4HPGD | |
| SCHEMBL28899836 | 0.80 | GRIN1 (0.46) | IDO1TDO2EIF4A3HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483366-B | Indole compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-09-16 | — | — | CN | disclosed |
| US-11267825-B2 | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-03-08 | — | — | US | disclosed |
| US-20200354379-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-12 | — | — | US | disclosed |
| EP-3704127-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2020-09-09 | — | — | EP | disclosed |
| CN-111448199-A | Novel highly active amino-thiazole-substituted indole-2-carboxamides having activity against Hepatitis B Virus (HBV) | 艾库里斯有限及两合公司 | 2020-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354379-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | IDO1 14/4885TDO2 210/4885EIF4A3 783/4885 |
| US-11267825-B2 | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | HCCS, BRD4, IDO2 | IDO1 5/4885TDO2 183/4885EIF4A3 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.